Figure 1.
Self-administered questionnaire to evaluate preferences for adalimumab 40 mg weekly or 80 mg every other week: (a) a 5-point Likert-type scale for preferences, (b) two closed questions for convenience and (c) a 100-point visual analogue scale to evaluate the patient preference to continue with one or another adalimumab regimen.
